Skip to content
Deep Lens (acquired by Paradigm) logo — Accelerating clinical trial matching in oncology

Deep Lens (acquired by Paradigm)

Accelerating clinical trial matching in oncology

Founded 2017 United States Columbus, United States 5 employees Series A Total: $17.20M AI, Health Care +2

General Information

Company Name Deep Lens (acquired by Paradigm)
Founded Year 2017
Location United States Columbus, United States
Employees 5
Industries AI, Health Care, Life Sciences +1
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Deep Lens (acquired by Paradigm). To contact Deep Lens (acquired by Paradigm), visit deeplens.ai.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Deep Lens (acquired by Paradigm) compare?

A PDF of Deep Lens (acquired by Paradigm) and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Deep Lens (acquired by Paradigm) soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Deep Lens (acquired by Paradigm)

Deep Lens, with the slogan "Accelerating clinical trial matching in oncology," is a digital healthcare company that was established in 2017 and is headquartered in the United States. The company focuses on leveraging AI, machine learning, and life sciences to expedite the recruitment of suitable cancer patients for clinical trials at the time of diagnosis through its proprietary platform, VIPER. Deep Lens' AI-driven cloud platform facilitates collaboration among care teams, trial coordinators, and oncologists, providing visibility into all available trials and enabling groundbreaking cancer research across various cancer types. The company recently secured a $14.00M Series A investment on 08 April 2019, with participation from notable investors including Rev1 Ventures, Service Provider Capital, Tamarind Hill, Sierra Ventures, and Northpond Ventures. Deep Lens operates at the intersection of AI, healthcare, and life sciences, addressing critical challenges in the clinical trial space, particularly within the oncology domain. As the demand for more efficient and precise patient matching in clinical trials grows, Deep Lens stands out as a promising player, poised to have a significant impact on the oncology research landscape.

Business keywords: Digital Healthcare, Clinical Trials, Oncology, AI-driven Platform, Cancer Patient Recruitment, Digital Pathology Workflow, AI Image Detection, Collaboration Platform, Cloud Storage, API Integration, Pathology Research, Pharmaceuticals, Cancer Research, Pathology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $14.00M 5
Rev1 Ventures, Service Provider Capital +3
08 Apr 2019
Seed Round $3.20M 3
Rev1 Ventures, Tamarind Hill +1
27 Sep 2018

Deep Lens (acquired by Paradigm) Alternatives & Competitors

View All Alternatives
Deep Lens (acquired by Paradigm) vs
Ancora.ai
Ancora.ai Switzerland

Ancora.ai is a patient-first, digital clinical trial navigation tool connecting cancer patients to c...

Grant
9 employees
AI, Big Data
Deep Lens (acquired by Paradigm) vs

AI-driven system connecting cancer patients to clinical trials in real time. Industrializing the onc...

Series B
103 employees
AI, Big Data
Deep Lens (acquired by Paradigm) vs
Leal Health
Leal Health United States

The AI-powered patient-centric decision-support platform for patients, healthcare providers, pharma,...

Series A
29 employees
AI, Health Care

FAQ About Deep Lens (acquired by Paradigm)

Accelerating clinical trial matching in oncology
Deep Lens (acquired by Paradigm) was founded in 2017.
Deep Lens (acquired by Paradigm) is headquartered in Columbus, United States.
Deep Lens (acquired by Paradigm) operates in AI, Health Care, Life Sciences and Machine Learning. Its work centres on Digital Healthcare, Clinical Trials, Oncology and AI-driven Platform.
Deep Lens (acquired by Paradigm) has approximately 5 employees.
Deep Lens (acquired by Paradigm) has completed 2 funding rounds, raising a total of $17.20M. The latest funding stage is Series A.
Top alternatives and competitors to Deep Lens (acquired by Paradigm) include Ancora.ai, Massive Bio, Leal Health, Oatmeal Health, XGC Software Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Deep Lens (acquired by Paradigm) and Ancora.ai are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Deep Lens (acquired by Paradigm), https://bouncewatch.com/company/deep-lens, updated 18 December 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout